Clinical trials
Scleroderma, Systemic trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 10 |
| Terminated | 6 |
| Active, not recruiting | 4 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 4 |
| Amgen | 3 |
| ISDIN | 3 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 3 |
| Actelion | 2 |
| AstraZeneca | 2 |
| Lakefront Biotherapeutics NV | 2 |
| Alejandro Cruz Utrilla | 1 |
| Artiva Biotherapeutics, Inc. | 1 |
| CRISPR Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Systemic | 36 |
| Scleroderma, Diffuse | 12 |
| Lung Diseases, Interstitial | 6 |
| Myositis | 6 |
| Arthritis, Rheumatoid | 5 |
| Lupus Erythematosus, Systemic | 5 |
| Autoimmune Diseases | 3 |
| Sjogren's Syndrome | 3 |
| Dermatomyositis | 2 |
| Hypertension, Pulmonary | 2 |
Trials
Showing 51 to 36 of 36. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.